CollPlant Biotechnologies Ltd. announced an extraordinary general meeting of shareholders for August 18, 2026, to vote on a reverse stock split and the elimination of par value. The company received a non-compliance notice from Nasdaq on March 23, 2026, due to its closing bid price falling below $1.00 for 30 consecutive business days. To regain compliance by the September 21, 2026 deadline, the board approved a reverse split framework ranging from 1-for-8 to 1-for-12, with the exact ratio and effective date to be determined by the board following shareholder approval. The filing also proposes amending the company's articles of association to eliminate the par value of its share capital. CollPlant Biotechnologies Ltd. operates in the biotechnology industry, specializing in the production of spider silk proteins for various applications.

CollPlant Biotechnologies Ltd. entered into a securities purchase agreement on June 29, 2026, for a private placement offering of 7,647,061 ordinary shares or pre-funded warrants. The offering includes series A and series B warrants to purchase up to 7,647,061 and 15,294,122 ordinary shares, respectively, at a combined price of $0.34 per share. The company expects gross proceeds of approximately $2.6 million to fund research, development, and strategic business combinations. H.C. Wainwright & Co., LLC is serving as the exclusive placement agent. The offering is expected to close around July 1, 2026. CollPlant Biotechnologies is a biotechnology company focused on plant-based recombinant human collagen.